Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma

28 Nov 2019

Abstract excerpt

B-cell lymphomas such as relapsed or refractory mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) are aggressive non-Hodgkin lymphomas (NHL). Although the BTK inhibitor ibrutinib has offered markedly improved clinical outcomes after disease relapse from multiple prior therapies 1 , 2 , ibrutinib resistance often develops in MCL, even following initial positive responses, and DLBCL is frequently...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Cutaneous lymphoproliferative disorders research
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31780660
DOI: 10.1038/s41408-019-0259-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphomaPMID 31780660Read ↗

Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancerSemantic proximity Read ↗

The Impact of the BCR Phenotype of Large B-cell Lymphoma on Ibrutinib Sensitivity.Semantic proximity Read ↗

Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.Semantic proximity Read ↗

ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trialSemantic proximity Read ↗

Auranofin Enhances Ibrutinib's Anticancer Activity in EGFR-Mutant Lung Adenocarcinoma.Semantic proximity Read ↗

Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphomaSemantic proximity Read ↗

Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma.Semantic proximity Read ↗

Orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients: Multi-center, Single-arm, Open-label, Phase 2 StudySemantic proximity Read ↗

FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapySemantic proximity Read ↗

BTK Inhibitors and BTK Degraders for the Treatment of Mantle Cell Lymphoma - Current Status and PerspectivesSemantic proximity Read ↗

The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisibSemantic proximity Read ↗

Induction of Aryl Hydrocarbon Receptor-Mediated Cancer Cell-Selective Apoptosis in Triple-Negative Breast Cancer Cells by a High-Affinity BenzimidazoisoquinolineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.